Pharmacy Times August 30, 2024
Despite questions and controversy around some clinical research, new understandings of the pathophysiology of the disease are pushing treatments forward.
Recent FDA approvals and new scientific understandings have given patients and practitioners renewed hope for the future of Alzheimer disease (AD), which has long presented a challenge. As new treatments finally reach the public, pharmacists will play a growing role in counseling and ensuring patient access.
History of AD
AD was first identified by Alois Alzheimer, a physician in Germany, when a woman named Auguste Deter was admitted to the institution where he worked. Alzheimer asked Deter to recall basic facts about her life and tested her understanding of where she was. Deter frequently responded, “I have lost myself, so...
Today's Sponsors
Today's Sponsor